본문 바로가기
  • Home

Clinical Study on Child’s Height Growth of Mixtures of Cynanchum wilfordii and Phlomis umbrosa Extract

  • Journal of Korean Medicine Rehabilitation
  • Abbr : JKMR
  • 2019, 29(1), pp.75-83
  • DOI : 10.18325/jkmr.2019.29.1.75
  • Publisher : The Korean Academy Of Oriental Rehabilitation Medicine
  • Research Area : Medicine and Pharmacy > Korean Medicine
  • Received : December 21, 2018
  • Accepted : January 8, 2019
  • Published : January 31, 2019

Ki Chan Ha 1 Baek Hyang Im 2 Hye Mi Kim 1 Young Mi Kim 1 Da Young Jeong 2 Seong Je Hong 3 Sang Keun Hong 3 Chang Min Choi 4

1헬스케어크레임스엔드멘내지멘트(주)
2헬스케어크레임스엔드멘내지멘트 (주)
3파낙산
4원광대학교 한의과대학 부인과학교실

Accredited

ABSTRACT

Objectives Previous animal studies have shown that mixtures of Cynanchum wilfordii and Phlomis umbrosa extract (IPLUS-CWPU) increases femur length and insulin like growth factor-1 (IGF-1) secretion. IPLUS-CWPU may thus be a promising ingredient in functional foods aimed at growing child's height. The purpose of the study is to investigate the effect of IPLUS-CWPU on height growth in children with short stature. Methods For this purpose, we recruited 90 children aged 4 to 12 years who had heights ranging from the 5th to 25th percentiles of Korean children's growth curve and randomized to either the IPLUS-CWPU or the placebo group. Results The IPLUS-CWPU group showed a significant increase in the change of the height growth compared to the placebo group after 20 weeks of administration (p=0.02). The height growth velosity also showed a statistically significant difference in the test group compared to the placebo group at 10 weeks (p=0.04). The IGF-1 levels showed a tendency to increase in the IPLUS-CWPU group (p=0.08). Moreover, the IPLUS-CWPU significantly increased IGF-1/IGFBP-3 ratio (p=0.02). However, there were no significant differences in blood biochemical parameters including growth hormone, bone age, thyroid stimulating hormone, and osteocalcin levels. Conclusions In conclusion, the data of this trial indicate that IPLUS-CWPU is effective and safe, generally well-tolerated without severe adverse events, in the treatment of children with short stature over a 20 weeks period. (J Korean Med Rehabil 2019;29(1):73-83)

Citation status

* References for papers published after 2023 are currently being built.